Intellia Therapeutics Inc
F:38I
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
Intellia Therapeutics Inc
F:38I
|
US |
|
A
|
AngloGold Ashanti Ltd
JSE:ANG
|
ZA |
|
V
|
Viant Technology Inc
NASDAQ:DSP
|
US |
|
F
|
Fresh Del Monte Produce Inc
DUS:FDM
|
US |
|
O
|
OneSpan Inc
F:VDY
|
US |
|
P
|
Pitney Bowes Inc
F:PBW
|
US |
|
M
|
Mosaic Co
XMUN:02M
|
US |
|
T
|
Tokyo Electron Ltd
OTC:TOELY
|
JP |
|
M
|
MFE-MEDIAFOREUROPE NV
MIL:MFEA
|
IT |
|
A
|
Applied Materials Inc
XMUN:AP2
|
US |
Wall St Price Targets
38I Price Targets Summary
Intellia Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
38I is 37.28 EUR with a low forecast of 12.09 EUR and a high forecast of 132.72 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 38I's stock price target?
Price Target
37.28
EUR
According to Wall Street analysts, the average 1-year price target for
38I is 37.28 EUR with a low forecast of 12.09 EUR and a high forecast of 132.72 EUR.
What is the Revenue forecast for Intellia Therapeutics Inc?
Projected CAGR
51%
Over the last 10 years, the compound annual growth rate for Revenue has been 27%. The projected CAGR for the next 8 years is 51%.